Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery.

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and ...

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery ...

ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.

Illumina has named Eric Green as chief medical officer, providing a home to the first National Institutes of Health director ...

Under an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company leading as founding participants, the Atlas is ...

Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute (NHGRI), Eric ...